Skip to main content
SpringerLink
Log in

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases

Final report of a prospective clinical trial

  • Original Research
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Preliminary results demonstrated that concurrent sunitinib and stereotactic body radiation therapy (SBRT) is an active regimen for metastases limited in number and extent. This analysis was conducted to determine the long-term survival and cancer control outcomes for this novel regimen. Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010. The majority of patients were treated with 37.5 mg sunitinib (days 1–28) and SBRT 50 Gy (days 8–12 and 15–19) and maintenance sunitinib was used in 39 % of patients. Median follow up for surviving patients is 3.6 years. The 4-year estimates for local control, distant control, progression-free and overall survival were 75 %, 40 %, 34 % and 29 %, respectively. At last follow-up, 26 % of patients were alive without evidence of disease, 7 % were alive with distant metastases, 48 % died from distant metastases, 2 % died from local progression, 13 % died from comorbid illness, and 4 % died from treatment-related toxicities. Patients with kidney and prostate primary tumors were associated with a significantly improved overall survival (hazard ratio = 0.25, p = 0.04). Concurrent sunitinib and SBRT is a promising approach for the treatment of oligometastases and further study of this novel combination is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10

    CAS  PubMed  Google Scholar 

  2. Andrews DW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665–1672

    Article  PubMed  Google Scholar 

  3. Patchell RA et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500

    Article  CAS  PubMed  Google Scholar 

  4. Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8(6):378–382

    CAS  PubMed  Google Scholar 

  5. Timmerman RD et al (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59(3):145–170

    Article  PubMed  Google Scholar 

  6. Lee MT et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27(10):1585–1591

    Article  PubMed  Google Scholar 

  7. Milano MT et al (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112(3):650–658

    Article  PubMed  Google Scholar 

  8. Rusthoven KE et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27(10):1579–1584

    Article  PubMed  Google Scholar 

  9. Rusthoven KE et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572–1578

    Article  PubMed  Google Scholar 

  10. Salama JK et al (2008) An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14(16):5255–5259

    Article  CAS  PubMed  Google Scholar 

  11. Salama JK et al (2012) Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118(11):2962–2970

    Article  PubMed  Google Scholar 

  12. Milano MT, et al (2011) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys

  13. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm—general principles. Nat Clin Pract Oncol 4(2):86–100

    Article  CAS  PubMed  Google Scholar 

  14. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884–896

    Article  CAS  PubMed  Google Scholar 

  15. Karaman MW et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26(1):127–132

    Article  CAS  PubMed  Google Scholar 

  16. Mauceri HJ et al (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394(6690):287–291

    Article  CAS  PubMed  Google Scholar 

  17. Schueneman AJ et al (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63(14):4009–4016

    CAS  PubMed  Google Scholar 

  18. Ozao-Choy J et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69(6):2514–2522

    Article  CAS  PubMed  Google Scholar 

  19. Ko JS et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6):2148–2157

    Article  CAS  PubMed  Google Scholar 

  20. Tong CC et al (2012) Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One 7(6):e36979

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Kao J et al (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 115(15):3571–3580

    Article  CAS  PubMed  Google Scholar 

  22. Wahl RL et al (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Milano MT et al (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83(3):878–886

    Article  PubMed  Google Scholar 

  24. Mehta N et al (2004) Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 25(6):1677–1683

    PubMed  Google Scholar 

  25. Rusthoven KE et al (2009) Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 48(4):578–583

    Article  CAS  PubMed  Google Scholar 

  26. Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  CAS  PubMed  Google Scholar 

  27. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5):487–494

    Article  CAS  PubMed  Google Scholar 

  28. Postow MA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925–931

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Kao J et al (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 77(1):12–19

    Google Scholar 

  30. Uematsu M et al (2001) Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 51(3):666–670

    Article  CAS  PubMed  Google Scholar 

  31. Timmerman RD et al (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25(8):947–952

    Article  PubMed  Google Scholar 

  32. Milano MT, Constine LS, Okunieff P (2008) Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 3:36

    Article  PubMed Central  PubMed  Google Scholar 

  33. Gerszten PC et al (2004) CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery 55(1):89–98, discussion 98–9

    PubMed  Google Scholar 

Download references

Acknowledgments

None

Conflict of interest

This study was partly supported by Pfizer investigator initiated award #2005-1082 and the Ellen Katz Foundation Award to J.K. Sunitinib was provided by Pfizer.

Role of funding source

This manuscript was reviewed by Pfizer prior to submission. However, the study sponsor played no involvement in study design, collection, analysis or interpretation of data, writing of the manuscript or the decision to submit the manuscript for publication.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Good Samaritan Hospital Medical Center, 1000 Montauk Highway, West Islip, NY, 11795, USA

    Johnny Kao

  2. Department of Medicine, New York University Medical Center, New York, NY, USA

    Chien-Ting Chen

  3. Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Medical Center, New York, NY, USA

    Charles C. L. Tong

  4. Department of Medical Oncology, Mount Sinai Medical Center, New York, NY, USA

    Stuart H. Packer & Max W. Sung

  5. Department of Surgery, Mount Sinai Medical Center, New York, NY, USA

    Myron Schwartz

  6. Department of Oncological Sciences, Mount Sinai Medical Center, New York, NY, USA

    Shu-hsia Chen

Authors
  1. Johnny Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chien-Ting Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles C. L. Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stuart H. Packer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Myron Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shu-hsia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Max W. Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johnny Kao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kao, J., Chen, CT., Tong, C.C.L. et al. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases. Targ Oncol 9, 145–153 (2014). https://doi.org/10.1007/s11523-013-0280-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-013-0280-y

Keywords

Search

Navigation